Related Experiment Videos
Antithrombotic therapy for percutaneous coronary intervention.
1Interventional Cardiology, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA.
Cardiology Clinics
|June 20, 2006
Summary
This review covers antiplatelet and antithrombotic therapies for percutaneous coronary interventions, discussing current and future pharmacologic agents. It guides interventionalists in selecting optimal treatments for patients undergoing these procedures.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Percutaneous coronary interventions (PCI) require effective antiplatelet and antithrombotic strategies.
- Optimizing pharmacotherapy in PCI is crucial for patient outcomes.
Purpose of the Study:
- To provide a comprehensive review of antiplatelet and antithrombotic therapies in contemporary PCI.
- To serve as a practical clinical guide for interventionalists regarding pharmacotherapy selection.
Main Methods:
- Review of past, present, and potential future pharmacologic agents.
- Analysis of clinical trials forming the basis of current and future standards of care.
Main Results:
- Discussion of established and emerging antiplatelet and antithrombotic agents.
- Evidence-based insights into pharmacotherapy selection for PCI.
Conclusions:
- Current evidence supports specific antiplatelet and antithrombotic regimens for PCI.
- Future therapies hold promise for further improving outcomes in PCI patients.